Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy.
Chemical-Clinical Analysis Unit, Laboratory Medicine Department, Niguarda Hospital, Milan, Italy.
Front Immunol. 2022 May 26;13:872667. doi: 10.3389/fimmu.2022.872667. eCollection 2022.
To evaluate the mean increase of anti-S IgG antibody titer between the basal, pre-booster level to the titer assessed 14 days after the booster dose of BNT162b2.
The RENAISSANCE study is an observational, longitudinal, prospective, population-based study, conducted on healthcare workers of Niguarda Hospital in Milan, Italy who received a BNT162b2 booster dose at least 180 days after their second dose or after positivity for SARS-CoV-2 and accepted to take part in the study. The RENAISSANCE study was conducted from January 1, 2021 through December 28, 2021.
1,738 subjects were enrolled among healthcare workers registered for the booster administration at our hospital. Overall, 0.4% of subjects were seronegative at the pre-booster evaluation, and 1 subject had a titer equal to 50 AU/ml: none of the evaluated subjects was seronegative after the booster dose. Thus, the efficacy of the booster in our population was universal. Mean increase of pre- to post-booster titer was more significant in subjects who never had SARS-CoV-2 (44 times CI 95% 42-46) compared to those who had it, before (33 times, CI 95% 13-70) or after the first vaccination cycle (12 times, CI 95% 11-14). Differently from sex, age and pre-booster titers affected the post-booster antibody response. Nevertheless, the post-booster titer was very similar in all subgroups, and independent of a prior exposure to SARS-CoV-2, pre-booster titer, sex or age.
Our study shows a potent universal antibody response of the booster dose of BNT162b2, regardless of pre-booster vaccine seronegativity.
评估 BNT162b2 加强针接种后 14 天，与基础、加强针前水平相比，抗-S IgG 抗体滴度的平均升高情况。
RENAISSANCE 研究是一项观察性、纵向、前瞻性、基于人群的研究，在意大利米兰的 Niguarda 医院进行，研究对象为在第二次接种后至少 180 天或 SARS-CoV-2 阳性后接受 BNT162b2 加强针接种并同意参与该研究的医护人员。RENAISSANCE 研究于 2021 年 1 月 1 日至 2021 年 12 月 28 日进行。
在我们医院登记接受加强针接种的医护人员中，共纳入 1738 名受试者。总体而言，0.4%的受试者在加强针前评估时血清阴性，1 名受试者的滴度为 50 AU/ml：无受试者在加强针接种后血清阴性。因此，在我们的人群中，加强针的疗效是普遍的。与曾感染 SARS-CoV-2（44 倍 CI 95% 42-46）、感染前（33 倍，CI 95% 13-70）或首次接种周期后（12 倍，CI 95% 11-14）相比，从未感染过 SARS-CoV-2 的受试者的预加强针至加强针后滴度增加更为显著。与性别不同，年龄和预加强针滴度影响加强后抗体反应。然而，在所有亚组中，加强后滴度非常相似，且与 SARS-CoV-2 既往暴露、预加强针滴度、性别或年龄无关。
我们的研究表明，BNT162b2 加强针接种后，无论预加强针疫苗血清学阴性与否，均可产生强大的普遍抗体反应。
